Anthony Sung
Overview:
I am dedicated to the treatment of hematologic malignancies through cellular therapies such as hematopoietic stem cell transplantation (HCT). My research focuses on strategies to reduce complications of HCT and ranges from preclinical studies using murine models of HCT to Phase 1 and Phase 2 clinical trials. Areas of interest include the role of the microbiota (the trillions of bacteria living in and on our bodies), nutrition, and exercise in modulating HCT outcomes such as graft-versus-host disease (GVHD) and infections. In addition to advancing new pharmacological and cellular immunotherapies in support of these goals, we also are developing mobile health technologies (mHealth) to monitor patients at home, both as part of our innovative home transplant program as well as to improve follow up care of all our patients when they return home after transplant.
Positions:
Associate Professor of Medicine
Member of the Duke Cancer Institute
Senior Fellow in the Center for the Study of Aging and Human Development
Education:
M.D. 2008
Residency, Osler Medical Housestaff Training Program
Fellowship, Hematology Oncology
Grants:
Patient-centered home-based hematopoietic stem cell transplantation
AZD9668 and Neutrophil Elastase Inhibition to Prevent Graft-versus-Host Disease
Keratinocyte targeted strategies for treatment of cutaneous GVHD
Mitigators of Radiation-Induced Endovascular Injury: Targeting Tie2 and Thrombocytopenia
Home Transplant to Preserve the Microbiota and Decrease GVHD
Publications:
Examining guidelines and new evidence in oncology nutrition: a position paper on gaps and opportunities in multimodal approaches to improve patient care.
Health behaviors, obesity, and marital status among cancer survivors: a MEPS study.
Conditioning Regimens are Associated with Distinct Patterns of Microbiota Injury in Allogeneic Hematopoietic Cell Transplantation.
Multi-omics analyses of radiation survivors identify radioprotective microbes and metabolites
MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT
